TheranosticTrials.org

Clinical Trial · NCT05930457

Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Overview

This is the study of 64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Phase

Phase 1

ClinicalTrials.gov

NCT05930457

Drug / Compound

FAPI-XT117

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • 3\. confirmed as malignant solid tumor by histopathology or clinical judgment
  • 4\. Patients will undergo 18F-FDG PET/CT examination

Exclusion

  • 1\. Known allergy to components of the investigational drug or its analogues
  • 2\. suspected to have a certain disease or condition that is not suitable for the study drug
  • 3\. Known pregnant or lactating women